RMD analyst estimates
ResMed (RMD) analyst ratings, the average price target and its range, and every firm's latest call.
RMD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | Mizuho Securities | ResMed (RMD) PT Raised to $270 at Mizuho | $270.00 |
| Oct 13, 2026 | Mizuho Securities | ResMed price target raised to $240 from $235 at Mizuho | $240.00 |
| Sep 15, 2026 | RBC Capital | RBC Capital Upgrades ResMed (RMD) to Outperform | $262.00 |
| Aug 31, 2026 | KeyBanc | ResMed price target raised to $267 from $255 at KeyBanc | $267.00 |
| Aug 19, 2026 | Redburn Partners | ResMed initiated with a Neutral at Rothschild & Co Redburn | $230.00 |
| Aug 7, 2026 | KeyBanc | ResMed price target lowered to $255 from $260 at KeyBanc | $255.00 |
| Aug 7, 2026 | Robert W. Baird | ResMed price target lowered to $213 from $217 at Baird | $213.00 |
| Jul 21, 2026 | UBS | ResMed (RMD) PT Lowered to $300 at UBS | $300.00 |
| Jul 16, 2026 | RBC Capital | ResMed downgraded to Sector Perform from Outperform at RBC Capital | $234.00 |
| Jul 15, 2026 | Mizuho Securities | ResMed price target lowered to $220 from $235 at Mizuho | $220.00 |
| Jul 10, 2026 | Jefferies | ResMed price target lowered to $225 from $240 at Jefferies | $225.00 |
| Jul 8, 2026 | Wells Fargo | ResMed price target lowered to $225 from $227 at Wells Fargo | $225.00 |
| Jul 8, 2026 | RBC Capital | ResMed price target lowered to $276 from $321 at RBC Capital | $276.00 |
| Jun 22, 2026 | KeyBanc | ResMed price target lowered to $266 from $290 at KeyBanc | $266.00 |
| Jun 17, 2026 | Morgan Stanley | Morgan Stanley Downgrades ResMed (RMD) to Equalweight | $230.00 |
- 12 firms rate RMD: 4 buy, 8 hold, 0 sell.
- The average price target is $246.89 from 9 analysts, from $213.00 to $300.00.
Updated 2026-11-02 17:13 UTC